1. Zhang S, Sun K, Zheng R, Zeng H, Wang S, Chen R, et al. Cancer incidence and mortality in China, 2015. J Nat Cancer Cent. 2021;1(1):2-11.
2. Sung H, Ferlay J, Siegel R L, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
3. Chen Y-P, Chan A T C, Le Q-T, Blanchard P, Sun Y,Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64-80.
4. Liu Z, Ji M-F, Huang Q-H, Fang F, Liu Q, Jia W-H, et al. Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in Southern China. Am J Epidemiol. 2013;177(3):242-50.
5. Liu Y, Huang Q, Liu W, Liu Q, Jia W, Chang E, et al. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. Int J Cancer. 2012;131(2):406-16.
6. Chang E T,Adami H O. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1765-77.
7. Guo X, Johnson R C, Deng H, Liao J, Guan L, Nelson G W, et al. Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of Southern China. Int J Cancer. 2009;124(12):2942-7.
8. Feng R, Chang E T, Liu Z, Liu Q, Cai Y, Zhang Z, et al. Body mass index, body shape, and risk of nasopharyngeal carcinoma: A population-based case-control study in Southern China. Cancer medicine. 2019;8(4):1835-1844.
9. Rottenberg Y, Levine H, Keinan-Boker L, Derazne E, Leiba A,Kark J D. Risk of nasopharyngeal carcinoma penetrates across immigrant generations: A migrant cohort study of 2.3 million Jewish Israeli adolescents. Int J Cancer. 2017;140(5):1060-1067.
10. Zeng F f, Xu C h, Liu Y t, Fan Y y, Lin X l, Lu Y k, et al. Choline and betaine intakes are associated with reduced risk of nasopharyngeal carcinoma in adults: a case-control study. Br J Cancer. 2014;110(3):808-16.
11. Deng T, Lyon C, Bergin S, Caligiuri M,Hsueh W. Obesity, Inflammation, and Cancer. Annu Rev Pathol. 2016;11:421-49.
12. Avgerinos K I, Spyrou N, Mantzoros C S,Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. 2019;92:121-135.
13. Scherer P E, Williams S, Fogliano M, Baldini G,Lodish H F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270(45):26746-9.
14. Hu E, Liang P,Spiegelman B M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;271(18):10697-703.
15. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley R E, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930-5.
16. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002;106(22):2767-70.
17. Pischon T, Girman C J, Hotamisligil G S, Rifai N, Hu F B,Rimm E B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291(14):1730-7.
18. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288-95.
19. Wei E K, Giovannucci E, Fuchs C S, Willett W C,Mantzoros C S. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005;97(22):1688-94.
20. Tworoger S S, Eliassen A H, Kelesidis T, Colditz G A, Willett W C, Mantzoros C S, et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab. 2007;92(4):1510-6.
21. Hofmann J N, Birmann B M, Teras L R, Pfeiffer R M, Wang Y, Albanes D, et al. Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals. Cancer Res. 2016;76(7):1935-41.
22. Li H, Stampfer M J, Mucci L, Rifai N, Qiu W, Kurth T, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem. 2010;56(1):34-43.
23. Man K, Ng K T, Xu A, Cheng Q, Lo C M, Xiao J W, et al. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin Cancer Res. 2010;16(3):967-77.
24. Cong L, Gasser J, Zhao J, Yang B, Li F,Zhao A Z. Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2. Endocr Relat Cancer. 2007;14(3):713-20.
25. Wang Y, Lam J B, Lam K S L, Liu J, Lam M C, Hoo R L C, et al. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res. 2006;66(23):11462-70.
26. Sengupta S, den Boon J A, Chen I H, Newton M A, Dahl D B, Chen M, et al. Genome-Wide Expression Profiling Reveals EBV-Associated Inhibition of MHC Class I Expression in Nasopharyngeal Carcinoma. Cancer Res. 2006;66(16):7999.
27. Bao Y-N, Cao X, Luo D-H, Sun R, Peng L-X, Wang L, et al. Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis. Cell cycle. 2014;13(12):1958-69.
28. Fan C, Wang J, Tang Y, Zhang S, Xiong F, Guo C, et al. Upregulation of long non-coding RNA LOC284454 may serve as a new serum diagnostic biomarker for head and neck cancers. BMC Cancer. 2020;20(1):917.
29. Bo H, Gong Z, Zhang W, Li X, Zeng Y, Liao Q, et al. Upregulated long non-coding RNA AFAP1-AS1 expression is associated with progression and poor prognosis of nasopharyngeal carcinoma. Oncotarget. 2015;6(24):20404-18.
30. Tang X-R, Li Y-Q, Liang S-B, Jiang W, Liu F, Ge W-X, et al. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. Lancet Oncol. 2018;19(3):382-393.
31. Lei Y, Li Y-Q, Jiang W, Hong X-H, Ge W-X, Zhang Y, et al. A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma. J Natl Cancer Inst. 2021;113(4):471-480.
32. Bose S, Yap L-F, Fung M, Starzcynski J, Saleh A, Morgan S, et al. The ATM tumour suppressor gene is down-regulated in EBV-associated nasopharyngeal carcinoma. J Pathol. 2009;217(3):345-52.
33. Zhang L, MacIsaac K D, Zhou T, Huang P-Y, Xin C, Dobson J R, et al. Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes. Mol Cancer Res. 2017;15(12):1722.
34. Shan C, Wang R, Wang S, Zhang Z, Xing C, Feng W, et al. Endogenous production of n-3 polyunsaturated fatty acids protects mice from carbon tetrachloride-induced liver fibrosis by regulating mTOR and Bcl-2/Bax signalling pathways. Exp Physiol. 2021;106(4):983-993.
35. Dalamaga M, Diakopoulos N,Mantzoros C. The Role of Adiponectin in Cancer: A Review of Current Evidence. Endocr Rev. 2012;33:547-94.
36. Kim A Y, Lee Y S, Kim K H, Lee J H, Lee H K, Jang S H, et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol. 2010;24(7):1441-52.
37. Shrestha A, Nepal S, Kim M J, Chang J H, Kim S H, Jeong G S, et al. Critical Role of AMPK/FoxO3A Axis in Globular Adiponectin-Induced Cell Cycle Arrest and Apoptosis in Cancer Cells. J Cell Physiol. 2016;231(2):357-69.
38. Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena N K,Sharma D. LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene. 2009;28(29):2621-33.
39. Li W, Saud S M, Young M R, Chen G,Hua B. Targeting AMPK for cancer prevention and treatment. Oncotarget. 2015;6(10):7365-78.
40. Luo Z, Zang M,Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol. 2010;6(3):457-70.
41. Okoshi R, Ozaki T, Yamamoto H, Ando K, Koida N, Ono S, et al. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem. 2008;283(7):3979-87.
42. Garcia Martinez J, Garcia-Inclan C, Suarez C, Llorente J L,Hermsen M A. DNA aneuploidy-specific therapy for head and neck squamous cell carcinoma. Head Neck. 2015;37(6):884-8.
43. Zakikhani M, Dowling R, Fantus I G, Sonenberg N,Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66(21):10269-73.
44. Bruun J M, Lihn A S, Verdich C, Pedersen S B, Toubro S, Astrup A, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab. 2003;285(3):E527-33.
45. Wolf A M, Wolf D, Rumpold H, Enrich B,Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun. 2004;323(2):630-5.
46. Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K-i, Matsuda K, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013;503(7477):493-9.
47. Liu B, Liu J, Wang J-g, Liu C-l,Yan H-j. AdipoRon improves cognitive dysfunction of Alzheimer’s disease and rescues impaired neural stem cell proliferation through AdipoR1/AMPK pathway. Exp Neurol. 2020;327:113249.
48. Ng R C-L, Jian M, Ma O K-F, Bunting M, Kwan J S-C, Zhou G-J, et al. Chronic oral administration of adipoRon reverses cognitive impairments and ameliorates neuropathology in an Alzheimer’s disease mouse model. Mol Psychiatry. 2020.
49. Nicolas S, Debayle D, Béchade C, Maroteaux L, Gay A-S, Bayer P, et al. Adiporon, an adiponectin receptor agonist acts as an antidepressant and metabolic regulator in a mouse model of depression. Transl Psychiatry. 2018;8(1):159.
50. Akimoto M, Maruyama R, Kawabata Y, Tajima Y,Takenaga K. Antidiabetic adiponectin receptor agonist AdipoRon suppresses tumour growth of pancreatic cancer by inducing RIPK1/ERK-dependent necroptosis. Cell Death Dis. 2018;9(8):804.
51. Zhang Y, Zhao J, Li R, Lau W B, Yuan Y X, Liang B, et al. AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings. Am J Physiol Endocrinol Metab. 2015;309(3):E275-82.